自己免疫性溶血性貧血治療の市場規模、シェア、動向分析レポート：タイプ別、薬剤クラス別、投与経路別、流通チャネル別、地域別、セグメント動向：2024年～2030年

自己免疫性溶血性貧血治療市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の自己免疫性溶血性貧血治療市場は、2024年から2030年にかけてCAGR 6.5%で成長し、2030年には11億6,000万米ドルに達すると予測されています。

世界の自己免疫性溶血性貧血（AIHA）症例数の増加、新規治療薬の導入、研究開発活動の活発化、政府の積極的な取り組みなどが成長を促進する主な要因です。例えば、フランスとデンマークにおけるAIHAの発症率は、それぞれ人口10万人当たり2.4人、17.0人と推定されています。

AIHA治療のための新薬開発のための研究開発が活発化しており、市場拡大の原動力になると予想されます。製薬会社や研究機関は、AIHAを管理するための新規かつ効果的な治療法の開発に積極的に取り組んでいます。例えば、Zenas BioPharma社は温熱性自己免疫性溶血性貧血（wAIHA）患者を対象としたオベキセリマブの開発に携わっています。この薬剤は臨床試験の第3相段階にあり、wAIHA患者における有効性と安全性が評価されています。同様に、ノバルティスAGは、温熱性自己免疫性溶血性貧血の治療が少なくとも1ラインは失敗した患者を対象に、イアナルマブ（VAY736）の安全性と有効性を評価する臨床試験を実施しています。

さらに、希少疾患を管理するためのヘルスケアサービスを向上させるために、政府機関の関与の増加や規制機関による有利なイニシアチブが実施されていることから、今後数年間で効果的な治療ソリューションの導入が増加すると予想されます。例えば、2019年12月、米国FDAはwAIHAの治療薬としてニポカリマブに希少疾病用医薬品の指定を与え、2019年7月、米国FDAは同じ適応症でニポカリマブにファストトラック指定を与えました。このような候補化合物に対する特別指定は、臨床試験と承認プロセスを迅速化することが期待されます。

主なプレーヤーは、市場での地位を強化するために買収や新製品開発など様々な市場戦略を採用しています。例えば、ブリストル・マイヤーズスクイブは2023年9月、ゼナス・バイオファーマから二機能性モノクローナル抗体オベキセリマブのアジア地域販売権を5,000万米ドルで取得しました。さらに、2022年6月、ライゲル・ファーマシューティカルズ社は、wAIHA患者を対象としたホスタマチニブの第3相臨床試験の結果を発表し、米国、カナダ、オーストラリア、西欧の各試験施設で、ホスタマチニブ治療を受けた患者に良好な持続的ヘモグロビン反応が認められたことを明らかにしました。

自己免疫性溶血性貧血治療市場レポート・ハイライト

• 自己免疫性溶血性貧血治療市場は、wAIHAの有病率の高さと治療率の高さから、2023年には温熱型自己免疫性溶血性貧血が市場を独占しました。
• 副腎皮質ステロイドは処方率が高いため、2023年に最大の市場シェアを占めました。さらに、副腎皮質ステロイドはAIHA治療の第一選択薬と考えられています。
• その他の薬剤クラス別セグメントは、生物学的製剤の研究開発と承認が増加していることから、今後数年間で最も急成長すると予測されています。
• 投与経路別では、患者中心のアプローチの採用が増加していることや、リルザブルチニブのような有望な経口薬がパイプラインに存在することから、経口薬が最も速い速度で成長すると予測されます。
• 北米は、疾患罹患率の高さ、強力な市場プレイヤーの存在、同地域の優れた償還政策などの要因により、市場を独占しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 自己免疫性溶血性貧血治療市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場 促進要因分析
  • 市場抑制要因分析
• 自己免疫性溶血性貧血治療市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析

第4章 自己免疫性溶血性貧血治療市場：タイプ推定・動向分析

• 世界の自己免疫性溶血性貧血治療市場：タイプダッシュボード
• 世界の自己免疫性溶血性貧血治療市場：タイプ変動分析
• 自己免疫性溶血性貧血治療の世界市場：タイプ別収益
• 温性自己免疫性溶血性貧血
• 寒冷自己免疫性溶血性貧血
• その他

第5章 自己免疫性溶血性貧血治療市場：薬剤クラスの推定・動向分析

• 世界の自己免疫性溶血性貧血治療市場：薬剤クラスダッシュボード
• 世界の自己免疫性溶血性貧血治療市場：薬剤クラスの変動分析
• 世界の自己免疫性溶血性貧血治療市場：薬剤クラス別収益
• コルチコステロイド
• 免疫抑制剤
• その他

第6章 自己免疫性溶血性貧血治療市場：投与経路の推定・動向分析

• 世界の自己免疫性溶血性貧血治療市場：投与経路ダッシュボード
• 世界の自己免疫性溶血性貧血治療市場：投与経路の変動分析
• 世界の自己免疫性溶血性貧血治療市場：投与経路別、収益別
• 注射可能
• オーラル
• その他

第7章 自己免疫性溶血性貧血治療市場：流通チャネルの推定・動向分析

• 世界の自己免疫性溶血性貧血治療市場：流通チャネルダッシュボード
• 世界の自己免疫性溶血性貧血治療市場：流通チャネル変動分析
• 世界の自己免疫性溶血性貧血治療市場：流通チャネル収益別
• 病院薬局
• 小売薬局
• オンライン薬局

第8章 自己免疫性溶血性貧血治療市場：タイプ、薬物クラス、投与経路、流通チャネル別の地域推定・動向分析

• 地域ダッシュボード
• 市場規模、予測トレンド分析、2018年から2030年：
• 北米
• 欧州
• アジア太平洋地域
• ラテンアメリカ
• 中東・アフリカ

第9章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • 主要ディストリビューターおよびチャネルパートナーのリスト
  • 主要顧客
  • 主要企業の市場シェア分析、2023年
  • F. Hoffmann-La Roche Ltd
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Lupin
  • Johnson &Johnson Services, Inc.
  • Novartis AG
  • Incyte
  • Rigel Pharmaceuticals, Inc.
  • Alpine Immune Sciences.

List of Tables

• Table 1 List of abbreviations
• Table 2 North America autoimmune hemolytic anemia treatment market, by country, 2018 - 2030 (USD Million)
• Table 3 North America autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
• Table 4 North America autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 5 North America autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 6 North America autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 7 U.S. autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
• Table 8 U.S. autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 9 U.S. autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 10 U.S. autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 11 Canada autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
• Table 12 Canada autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 13 Canada autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 14 Canada autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 15 Europe autoimmune hemolytic anemia treatment market, by country, 2018 - 2030 (USD Million)
• Table 16 Europe autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
• Table 17 Europe autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 18 Europe autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 19 Europe autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 20 Germany autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
• Table 21 Germany autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 22 Germany autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 23 Germany autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 24 UK autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
• Table 25 UK autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 26 UK autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 27 UK autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 28 France autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
• Table 29 France autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 30 France autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 31 France autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 32 Italy autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
• Table 33 Italy autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 34 Italy autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 35 Italy autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 36 Spain autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
• Table 37 Spain autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 38 Spain autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 39 Spain autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 40 Denmark autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
• Table 41 Denmark autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 42 Denmark autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 43 Denmark autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 44 Sweden autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
• Table 45 Sweden autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 46 Sweden autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 47 Sweden autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 48 Norway autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
• Table 49 Norway autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 50 Norway autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 51 Norway autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 52 Asia Pacific autoimmune hemolytic anemia treatment market, by region, 2018 - 2030 (USD Million)
• Table 53 Asia Pacific autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
• Table 54 Asia Pacific autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 55 Aisa Pacific autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 56 Aisa Pacific autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 57 China autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
• Table 58 China autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 59 China autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 60 China autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 61 Japan autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
• Table 62 Japan autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 63 Japan autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 64 Japan autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 65 India autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
• Table 66 India autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 67 India autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 68 India autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 69 South Korea autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
• Table 70 South Korea autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 71 South Korea autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 72 South Korea autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 73 Australia autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
• Table 74 Australia autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 75 Australia autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 76 Australia autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 77 Thailand autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
• Table 78 Thailand autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 79 Thailand autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 80 Thailand autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 81 Latin America autoimmune hemolytic anemia treatment market, by region, 2018 - 2030 (USD Million)
• Table 82 Latin America autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
• Table 83 Latin America autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 84 Latin America autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 85 Latin America autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 86 Brazil autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
• Table 87 Brazil autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 88 Brazil autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 89 Brazil autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 90 Mexico autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
• Table 91 Mexico autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 92 Mexico autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 93 Mexico autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 94 Argentina autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
• Table 95 Argentina autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 96 Argentina autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 97 Argentina autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 98 MEA autoimmune hemolytic anemia treatment market, by region, 2018 - 2030 (USD Million)
• Table 99 MEA autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
• Table 100 MEA autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 101 MEA autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 102 MEA autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 103 South Africa autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
• Table 104 South Africa autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 105 South Africa autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 106 South Africa autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 107 Saudi Arabia autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
• Table 108 Saudi Arabia autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 109 Saudi Arabia autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 110 Saudi Arabia autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 111 UAE autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
• Table 112 UAE autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 113 UAE autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 114 UAE autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
• Table 115 Kuwait autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
• Table 116 Kuwait autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
• Table 117 Kuwait autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
• Table 118 Kuwait autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews in North America
• Fig. 5 Primary interviews in Europe
• Fig. 6 Primary interviews in APAC
• Fig. 7 Primary interviews in Latin America
• Fig. 8 Primary interviews in MEA
• Fig. 9 Market research approaches
• Fig. 10 Value-chain-based sizing & forecasting
• Fig. 11 QFD modeling for market share assessment
• Fig. 12 Market formulation & validation
• Fig. 13 Autoimmune hemolytic anemia treatment market: market outlook
• Fig. 14 Autoimmune hemolytic anemia treatment competitive insights
• Fig. 15 Parent market outlook
• Fig. 16 Related/ancillary market outlook
• Fig. 17 Autoimmune hemolytic anemia treatment market driver impact
• Fig. 18 Autoimmune hemolytic anemia treatment market restraint impact
• Fig. 19 Autoimmune hemolytic anemia treatment market: Type movement analysis
• Fig. 20 Autoimmune hemolytic anemia treatment market: Type outlook and key takeaways
• Fig. 21 Warm autoimmune hemolytic anemia market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 Cold autoimmune hemolytic anemia market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 24 Autoimmune hemolytic anemia treatment market: Drug class movement analysis
• Fig. 25 Autoimmune hemolytic anemia treatment market: Drug class outlook and key takeaways
• Fig. 26 Corticosteroids market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 27 Immunosuppressive agents market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 28 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 29 Autoimmune hemolytic anemia treatment market: Route of administration movement analysis
• Fig. 30 Autoimmune hemolytic anemia treatment market: Route of administration outlook and key takeaways
• Fig. 31 Oral market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 32 Injectable market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 33 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 34 Autoimmune hemolytic anemia treatment market: Distribution channel movement analysis
• Fig. 35 Autoimmune hemolytic anemia treatment market: Distribution channel outlook and key takeaways
• Fig. 36 Hospital pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 37 Retail pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 38 Online pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 39 Global Autoimmune hemolytic anemia treatment market: Regional movement analysis
• Fig. 40 Global Autoimmune hemolytic anemia treatment market: Regional outlook and key takeaways
• Fig. 41 Global Autoimmune hemolytic anemia treatment market share and leading players
• Fig. 42 North America, by country
• Fig. 43 North America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 44 U.S. key country dynamics
• Fig. 45 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 46 Canada key country dynamics
• Fig. 47 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 48 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 49 UK key country dynamics
• Fig. 50 UK market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 51 Germany key country dynamics
• Fig. 52 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 53 France key country dynamics
• Fig. 54 France market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 55 Italy key country dynamics
• Fig. 56 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 57 Spain key country dynamics
• Fig. 58 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 59 Denmark key country dynamics
• Fig. 60 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 61 Sweden key country dynamics
• Fig. 62 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 63 Norway key country dynamics
• Fig. 64 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 65 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 66 China key country dynamics
• Fig. 67 China market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 68 Japan key country dynamics
• Fig. 69 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 70 India key country dynamics
• Fig. 71 India market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 72 Thailand key country dynamics
• Fig. 73 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 74 South Korea key country dynamics
• Fig. 75 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 76 Australia key country dynamics
• Fig. 77 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 78 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 79 Brazil key country dynamics
• Fig. 80 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 81 Mexico key country dynamics
• Fig. 82 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 83 Argentina key country dynamics
• Fig. 84 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 85 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 86 South Africa key country dynamics
• Fig. 87 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 88 Saudi Arabia key country dynamics
• Fig. 89 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 90 UAE key country dynamics
• Fig. 91 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 92 Kuwait key country dynamics
• Fig. 93 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 94 Market share of key market players- 2023

Autoimmune Hemolytic Anemia Treatment Market Growth & Trends:

The global autoimmune hemolytic anemia treatment market is anticipated to reach USD 1.16 billion by 2030, growing at a CAGR of 6.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increasing number of autoimmune hemolytic anemia (AIHA) cases worldwide, introduction of novel therapeutic drugs, increasing R&D activities, and favorable government initiatives are some of key factors driving the growth. For instance, the incidence of AIHA in France and Denmark is estimated at around 2.4 per 100,000 and 17.0 per 100,000 population, respectively.

Increasing research & activities to develop novel drugs for AIHA treatment is anticipated to drive the market expansion. Pharmaceutical companies and research institutes are actively involved in the development of novel and effective treatment options to manage AIHA. For instance, Zenas BioPharma is involved in the development of obexelimab for patients with warm autoimmune hemolytic anemia(wAIHA). The drug is in phase 3 of clinical trials and is being evaluated for efficacy and safety in patients with wAIHA. Similarly, Novartis AG is conducting clinical trials to evaluate the safety and efficacy of Ianalumab (VAY736) in patients who failed at least one line of treatment for warm autoimmune hemolytic anemia.

Moreover, the increasing involvement of government institutes and favorable initiatives undertaken by regulatory bodies to improve healthcare services to manage rare diseases are expected to increase the introduction of effective therapeutic solutions in the coming years. For instance, in December 2019, the U.S. FDA granted orphan drug designation to nipocalimab for the treatment of wAIHA and in July 2019, the U.S. FDA granted fast track designation for nipocalimab for the same indication. Such special designations for investigating candidates are expected to speed up the clinical trials and approval process.

Key players are adopting various market strategies such as acquisition and new product development to strengthen their market position. For instance, in September 2023, Bristol Myers Squibb acquired Asian regional market rights for bifunctional monoclonal antibody obexelimab from Zenas BioPharma, paying USD 50 million. Moreover, in June 2022, Rigel Pharmaceuticals, Inc. announced the results of phase 3 clinical trials of fostamatinib in patients with wAIHA, showing that patients treated with fostamatinib had a favorable durable hemoglobin response at the U.S., Canadian, Australian, and Western European trial sites.

Autoimmune Hemolytic Anemia Treatment Market Report Highlights:

• The warm autoimmune hemolytic anemia type segment dominated the market in 2023 owing to a high prevalence of wAIHA and treatment rate.
• The corticosteroids segment held the largest market share in 2023, owing to the high prescription rate. Moreover, corticosteroids are considered as the first line of treatment for AIHA.
• The other drug class segment is projected to experience the fastest growth during the projected years owing to increasing R&D and approval of biological drugs.
• In the route of administration segment, oral drugs are anticipated to grow at the fastest rate owing to the increasing adoption of patient-centric approaches and the presence of promising oral drugs such as rilzabrutinib in the pipeline.
• North America dominated the market owing to factors such as high disease incidence, the presence of strong market players, and better reimbursement policies in the region.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Drug Class
  • 1.2.3. Route of Administration
  • 1.2.4. Distribution Channel
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type and drug class outlook
  • 2.2.2. Route of administration and distribution channel outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Autoimmune Hemolytic Anemia Treatment Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing incidence of disease
    • 3.2.1.2. Increasing geriatric population
    • 3.2.1.3. Rise in R&D activities
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost of novel drug development for rare diseases
• 3.3. Autoimmune Hemolytic Anemia Treatment Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's Five Forces
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Autoimmune Hemolytic Anemia Treatment Market: Type Estimates & Trend Analysis

• 4.1. Global Autoimmune Hemolytic Anemia Treatment Market: Type Dashboard
• 4.2. Global Autoimmune Hemolytic Anemia Treatment Market: Type Movement Analysis
• 4.3. Global Autoimmune Hemolytic Anemia Treatment Market by Type, Revenue
• 4.4. Warm Autoimmune Hemolytic Anemia
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Cold Autoimmune Hemolytic Anemia
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Others
  • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Autoimmune Hemolytic Anemia Treatment Market: Drug Class Estimates & Trend Analysis

• 5.1. Global Autoimmune Hemolytic Anemia Treatment Market: Drug Class Dashboard
• 5.2. Global Autoimmune Hemolytic Anemia Treatment Market: Drug Class Movement Analysis
• 5.3. Global Autoimmune Hemolytic Anemia Treatment Market by Drug Class, Revenue
• 5.4. Corticosteroids
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Immunosuppressive agents
  • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Others
  • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Autoimmune Hemolytic Anemia Treatment Market: Route of Administration Estimates & Trend Analysis

• 6.1. Global Autoimmune Hemolytic Anemia Treatment Market: Route of Administration Dashboard
• 6.2. Global Autoimmune Hemolytic Anemia Treatment Market: Route of Administration Movement Analysis
• 6.3. Global Autoimmune Hemolytic Anemia Treatment Market by Route of Administration, Revenue
• 6.4. Injectable
  • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Oral
  • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Autoimmune Hemolytic Anemia Treatment Market: Distribution Channel Estimates & Trend Analysis

• 7.1. Global Autoimmune Hemolytic Anemia Treatment Market: Distribution Channel Dashboard
• 7.2. Global Autoimmune Hemolytic Anemia Treatment Market: Distribution Channel Movement Analysis
• 7.3. Global Autoimmune Hemolytic Anemia Treatment Market by Distribution Channel, Revenue
• 7.4. Hospital Pharmacy
  • 7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Retail Pharmacy
  • 7.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Online Pharmacy
  • 7.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Autoimmune Hemolytic Anemia Treatment Market: Regional Estimates & Trend Analysis by Type, Drug Class, Route of Administration, and Distribution Channel

• 8.1. Regional Dashboard
• 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.3. North America
  • 8.3.1. U.S.
    • 8.3.1.1. Key country dynamics
    • 8.3.1.2. Regulatory framework/ reimbursement structure
    • 8.3.1.3. Competitive scenario
    • 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.2. Canada
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Regulatory framework/ reimbursement structure
    • 8.3.2.3. Competitive scenario
    • 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 8.4. Europe
  • 8.4.1. UK
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework/ reimbursement structure
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.3. France
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.4. Italy
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework/ reimbursement structure
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.5. Spain
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Regulatory framework/ reimbursement structure
    • 8.4.5.3. Competitive scenario
    • 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.6. Norway
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Regulatory framework/ reimbursement structure
    • 8.4.6.3. Competitive scenario
    • 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.7. Sweden
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Regulatory framework/ reimbursement structure
    • 8.4.7.3. Competitive scenario
    • 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.8. Denmark
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Regulatory framework/ reimbursement structure
    • 8.4.8.3. Competitive scenario
    • 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Japan
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.2. China
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. India
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.4. Australia
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Latin America
  • 8.6.1. Brazil
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.2. Mexico
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.3. Argentina
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework/ reimbursement structure
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. MEA
  • 8.7.1. South Africa
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.4. Kuwait
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Vendor Landscape
  • 9.3.1. List of key distributors and channel partners
  • 9.3.2. Key customers
  • 9.3.3. Key company market share analysis, 2023
  • 9.3.4. F. Hoffmann-La Roche Ltd
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Product benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. Viatris Inc.
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Product benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. Teva Pharmaceutical Industries Ltd.
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Product benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. Sanofi
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Product benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. Lupin
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Product benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. Johnson & Johnson Services, Inc.
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Product benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. Novartis AG
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Product benchmarking
    • 9.3.10.4. Strategic initiatives
  • 9.3.11. Incyte
    • 9.3.11.1. Company overview
    • 9.3.11.2. Financial performance
    • 9.3.11.3. Product benchmarking
    • 9.3.11.4. Strategic initiatives
  • 9.3.12. Rigel Pharmaceuticals, Inc.
    • 9.3.12.1. Company overview
    • 9.3.12.2. Financial performance
    • 9.3.12.3. Product benchmarking
    • 9.3.12.4. Strategic initiatives
  • 9.3.13. Alpine Immune Sciences.
    • 9.3.13.1. Company overview
    • 9.3.13.2. Financial performance
    • 9.3.13.3. Product benchmarking
    • 9.3.13.4. Strategic initiatives